Paper6646201
Amplification and expression of the c-myc oncogene in human lung cancer cell lines.
Little CD and 4 others. Nature, 1983. Cited by 935 papers, by iCite.
Cite this record
ConductScience Library. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Papers, record 6646201. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6646201
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Amplification | Major topic |
| Lung Neoplasms | Major topic |
| Oncogenes | Major topic |
| Cell Line | |
| DNA, Neoplasm | |
| Gene Expression Regulation | |
| Humans | |
| RNA, Neoplasm |
Source PubMed
Cited by257
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 935 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42386735 | Developmental timing distinguishes pediatric and adult cancers through retention and rewiring mechanisms. | Nat Commun | 2026 | https://conductscience.org/library/papers/42386735 | PubMed |
| 41044455 | A deep single cell mass cytometry approach to capture canonical and noncanonical cell cycle states. | Nat Commun | 2025 | https://conductscience.org/library/papers/41044455 | PubMed |
| 41041628 | What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer? | JTO Clin Res Rep | 2025 | https://conductscience.org/library/papers/41041628 | PubMed |
| 40702511 | Comparative analysis of hybrid-SNP microarray and nanopore sequencing for detection of large-sized copy number variants in the human genome. | Mol Cytogenet | 2025 | https://conductscience.org/library/papers/40702511 | PubMed |
| 40280500 | Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors. | Biochim Biophys Acta Rev Cancer | 2025 | https://conductscience.org/library/papers/40280500 | PubMed |
| 40214491 | Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies. | Cells | 2025 | https://conductscience.org/library/papers/40214491 | PubMed |
| 40211072 | Challenges of small cell lung cancer heterogeneity and phenotypic plasticity. | Nat Rev Cancer | 2025 | https://conductscience.org/library/papers/40211072 | PubMed |
| 39995768 | Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival. | Lung Cancer (Auckl) | 2025 | https://conductscience.org/library/papers/39995768 | PubMed |
| 39567755 | Breathing new insights into the role of mutant p53 in lung cancer. | Oncogene | 2025 | https://conductscience.org/library/papers/39567755 | PubMed |
| 39511409 | Nuclear versus cytoplasmic IKKα signaling in keratinocytes leads to opposite skin phenotypes and inflammatory responses, and a different predisposition to cancer. | Oncogene | 2025 | https://conductscience.org/library/papers/39511409 | PubMed |
| 39453005 | Peptide-Conjugated Vascular Endothelial Extracellular Vesicles Encapsulating Vinorelbine for Lung Cancer Targeted Therapeutics. | Nanomaterials (Basel) | 2024 | https://conductscience.org/library/papers/39453005 | PubMed |
| 39335124 | Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39335124 | PubMed |
| 39295275 | ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. | Mol Cancer Ther | 2024 | https://conductscience.org/library/papers/39295275 | PubMed |
| 38747975 | MYC Family Amplification Dictates Sensitivity to BET Bromodomain Protein Inhibitor Mivebresib (ABBV075) in Small-Cell Lung Cancer. | Mol Cancer Res | 2024 | https://conductscience.org/library/papers/38747975 | PubMed |
| 38386926 | Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs. | Cancer Discov | 2024 | https://conductscience.org/library/papers/38386926 | PubMed |
| 37258584 | Peptides as multifunctional players in cancer therapy. | Exp Mol Med | 2023 | https://conductscience.org/library/papers/37258584 | PubMed |
| 37110707 | Euonymus sachalinensis Induces Apoptosis by Inhibiting the Expression of c-Myc in Colon Cancer Cells. | Molecules | 2023 | https://conductscience.org/library/papers/37110707 | PubMed |
| 37098540 | MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/37098540 | PubMed |
| 37046804 | Lipid Metabolic Reprogramming in Embryonal Neoplasms with MYCN Amplification. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37046804 | PubMed |
| 36650528 | An antisense amido-bridged nucleic acid gapmer oligonucleotide targeting SRRM4 alters REST splicing and exhibits anti-tumor effects in small cell lung cancer and prostate cancer cells. | Cancer Cell Int | 2023 | https://conductscience.org/library/papers/36650528 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6646201
GET https://conductscience.org/api/papers/v1/6646201/cited_by?page=2